Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.

• Status: Completed
• Trial end date: 2005-06-01

Summary

The primary objective of the study is to compare the efficacy of levosimendan and dobutamine on all-cause mortality in the 180 days following randomization.

• Phase: Phase 3

Details

• Lead Sponsor: Abbott
• Collaborator: Orion Corporation, Orion Pharma
• Treatments: Dobutamine; Simendan